Literature DB >> 8303684

Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets.

S R Torr-Brown1, B E Sobel.   

Abstract

Although platelets contain approximately 90% of the total amount of plasminogen activator inhibitor type-1 (PAI-1) present in blood, the functional significance of PAI-1 in platelets has been controversial. Most assessments of platelet PAI-1 have been performed with platelet lysates in which the PAI-1 derived from platelets may have been inactivated during the course of lysis. This study was performed to determine whether elaboration of PAI-1 from platelets activated physiologically by thrombolysis of pre-formed clots inhibits activation of plasminogen by tissue-type plasminogen activator (t-PA). Human whole blood clots were formed in Chandler tubes, and release of PAI-1 from platelets was quantified during and after clot formation. Subsequently, clots were placed in different Chandler tubes, and the effects of platelet PAI-1 on lysis induced by t-PA were characterized. Both the activity and concentrations of PAI-1 elaborated from platelets peaked approximately 15 min after induction of clotting. Induction of clot lysis with t-PA, 1,000 to 5,000 ng/ml, was inhibited by platelet-rich compared with platelet-poor plasma. Platelets inhibited lysis of preformed clots by t-PA and plasminogen in buffer solutions as well. Both the inhibition of clot lysis and accumulation of PAI-1 released from platelets were prevented by attenuation of thrombin-mediated activation of platelets with hirudin. Furthermore, the PAI-1 mediated inhibition was obviated by blockade of PAI-1 activity with a neutralizing monoclonal antibody to PAI-1. These results indicate that platelets inhibit clot lysis induced by t-PA by releasing functionally active PAI-1.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8303684     DOI: 10.1016/0049-3848(93)90241-f

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  9 in total

Review 1.  Enhanced spontaneous thrombolysis: a new therapeutic challenge.

Authors:  I B Kovacs; D A Gorog; J Yamamoto
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

Review 2.  Plasminogen activator inhibitor type-1 (part two): role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents.

Authors:  K Huber
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 3.  PAI-1: A Major Player in the Vascular Dysfunction in Obstructive Sleep Apnea?

Authors:  Mohammad Badran; David Gozal
Journal:  Int J Mol Sci       Date:  2022-05-15       Impact factor: 6.208

Review 4.  Glycoprotein IIb/IIIa receptor inhibitor-thrombolytic combination therapy for acute myocardial infarction.

Authors:  Ara M Maranian; Steven R Steinhubl
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931

Review 5.  Antiplatelet therapy in cardiovascular disease.

Authors:  M W H Behan; R F Storey
Journal:  Postgrad Med J       Date:  2004-03       Impact factor: 2.401

6.  Changes in spontaneous thrombolytic activity during progression of atherosclerosis in Apo-/- and LDLR-/- double knockout mice.

Authors:  Takumi Sato; Manami Yoshimura; Tomohide Sanda; Kanae Hyodo; Junichiro Yamamoto; Hiromitu Ishii; Tsutomu Yamashita
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

7.  Platelets retain high levels of active plasminogen activator inhibitor 1.

Authors:  Helén Brogren; Karin Wallmark; Johanna Deinum; Lena Karlsson; Sverker Jern
Journal:  PLoS One       Date:  2011-11-01       Impact factor: 3.240

Review 8.  Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Front Cardiovasc Med       Date:  2020-12-22

Review 9.  A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?

Authors:  Machteld Sillen; Paul J Declerck
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.